158 related articles for article (PubMed ID: 1639630)
1. T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides.
Gedde-Dahl T; Eriksen JA; Thorsby E; Gaudernack G
Hum Immunol; 1992 Apr; 33(4):266-74. PubMed ID: 1639630
[TBL] [Abstract][Full Text] [Related]
2. Overlapping epitopes encompassing a point mutation (12 Gly-->Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells.
Fossum B; Gedde-Dahl T; Hansen T; Eriksen JA; Thorsby E; Gaudernack G
Eur J Immunol; 1993 Oct; 23(10):2687-91. PubMed ID: 7691613
[TBL] [Abstract][Full Text] [Related]
3. T cell clones specific for p21 ras-derived peptides: characterization of their fine specificity and HLA restriction.
Gedde-Dahl T; Fossum B; Eriksen JA; Thorsby E; Gaudernack G
Eur J Immunol; 1993 Mar; 23(3):754-60. PubMed ID: 8449222
[TBL] [Abstract][Full Text] [Related]
4. Binding of ras oncogene peptides to purified HLA-DQ(alpha 1*0102,beta 1*0602) and -DR(alpha,beta 1*0101) molecules.
Johansen BH; Gedde-Dahl T; Sollid LM; Vartdal F; Thorsby E; Gaudernack G
Scand J Immunol; 1994 Jun; 39(6):607-12. PubMed ID: 8009176
[TBL] [Abstract][Full Text] [Related]
5. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61).
Gedde-Dahl T; Spurkland A; Eriksen JA; Thorsby E; Gaudernack G
Int Immunol; 1992 Nov; 4(11):1331-7. PubMed ID: 1282032
[TBL] [Abstract][Full Text] [Related]
6. T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA.
Gedde-Dahl T; Spurkland A; Fossum B; Wittinghofer A; Thorsby E; Gaudernack G
Eur J Immunol; 1994 Feb; 24(2):410-4. PubMed ID: 7507844
[TBL] [Abstract][Full Text] [Related]
7. Oncogene-derived peptides: a new class of tumor rejection antigens?
Gedde-Dahl T; Olsen BH; Thorsby E; Gaudernack G
Transplant Proc; 1993 Feb; 25(1 Pt 2):1385-6. PubMed ID: 8442151
[No Abstract] [Full Text] [Related]
8. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes.
Peace DJ; Chen W; Nelson H; Cheever MA
J Immunol; 1991 Mar; 146(6):2059-65. PubMed ID: 2005390
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of immune response by an analog of the antigenic peptide in a human T-cell clone recognizing mutated Ras-derived peptides.
Yokomizo H; Matsushita S; Fujisao S; Murakami S; Fujita H; Shirouzu M; Yokoyama S; Ogawa M; Nishimura Y
Hum Immunol; 1997 Jan; 52(1):22-32. PubMed ID: 9021406
[TBL] [Abstract][Full Text] [Related]
10. Binding of mutated Ras- and p53-derived peptides to HLA-DR molecules.
Murakami S; Yokomizo H; Matsushita S; Ogawa M; Nishimura Y
Immunol Lett; 1996 Mar; 49(3):149-53. PubMed ID: 8739309
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of T cells specific for a particular peptide/HLA-DQ complex.
Spurkland A; Gedde-Dahl T; Hansen T; Vartdal F; Gaudernack G; Thorsby E
Hum Immunol; 1994 Jan; 39(1):61-8. PubMed ID: 8181964
[TBL] [Abstract][Full Text] [Related]
12. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T-lymphocyte responses against mutated p21 ras peptides: an analysis of specific T-cell-receptor gene usage.
Juretic A; Jürgens-Göbel J; Schaefer C; Noppen C; Willimann TE; Kocher T; Zuber M; Harder F; Heberer M; Spagnoli GC
Int J Cancer; 1996 Nov; 68(4):471-8. PubMed ID: 8945618
[TBL] [Abstract][Full Text] [Related]
14. T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.
Cheever MA; Chen W; Disis ML; Takahashi M; Peace DJ
Ann N Y Acad Sci; 1993 Aug; 690():101-12. PubMed ID: 8103658
[TBL] [Abstract][Full Text] [Related]
15. Induction in transgenic mice of HLA-A2.1-restricted cytotoxic T cells specific for a peptide sequence from a mutated p21ras protein.
Escobar P; Yu Z; Terskikh A; Holmes N; Corradin G; Mach JP; Healy F
Clin Exp Immunol; 1999 May; 116(2):214-9. PubMed ID: 10337009
[TBL] [Abstract][Full Text] [Related]
16. p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp).
Fossum B; Gedde-Dahl T; Breivik J; Eriksen JA; Spurkland A; Thorsby E; Gaudernack G
Int J Cancer; 1994 Jan; 56(1):40-5. PubMed ID: 7903287
[TBL] [Abstract][Full Text] [Related]
17. Cross-reactive epitopes and HLA-restriction elements in human T cell recognition of the Mycobacterium leprae 18-kD heat shock protein.
Mustafa AS; Lundin KE; Meloen RH; Oftung F
Clin Exp Immunol; 2000 Apr; 120(1):85-92. PubMed ID: 10759768
[TBL] [Abstract][Full Text] [Related]
18. Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201.
Van Elsas A; Nijman HW; Van der Minne CE; Mourer JS; Kast WM; Melief CJ; Schrier PI
Int J Cancer; 1995 May; 61(3):389-96. PubMed ID: 7729952
[TBL] [Abstract][Full Text] [Related]
19. Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers.
Shono Y; Tanimura H; Iwahashi M; Tsunoda T; Tani M; Tanaka H; Matsuda K; Yamaue H
Br J Cancer; 2003 Feb; 88(4):530-6. PubMed ID: 12592366
[TBL] [Abstract][Full Text] [Related]
20. Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras.
Gedde-Dahl T; Nilsen E; Thorsby E; Gaudernack G
Cancer Immunol Immunother; 1994 Feb; 38(2):127-34. PubMed ID: 8306368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
